POST Online Media Lite Edition



 

3 drug firms accused of illegal market sharing in UK

Christian Fernsby |
The CMA has provisionally found that 3 drug firms signed an illegal agreement that resulted in significant price hikes for an essential medicine.

Article continues below



Topics: DRUG    ILLEGAL    MARKET    UK   

The Competition and Markets Authority (CMA) sets out its provisional view that, in 2016, pharmaceutical company Aspen unlawfully agreed to pay 2 other firms, Amilco and Tiofarma, to stay out of the UK market for fludrocortisone acetate tablets. This is a prescription-only medicine that thousands of patients rely on to treat primary or secondary adrenal insufficiency, commonly known as Addison’s Disease.

This alleged illegal agreement protected Aspen’s UK monopoly in relation to the supply of the drug to the NHS and gave the firm the opportunity to increase prices by up to 1,800%.

The CMA has provisionally found that Tiofarma and Amilco colluded with Aspen by agreeing to stay out of the market so that Aspen could maintain its position as the sole UK supplier of fludrocortisone. In exchange, it is alleged that Tiofarma was made the sole manufacturer of fludrocortisone for direct sale in the UK, and Amilco received a 30% share of the increased prices that Aspen was able to charge.


What to read next

George Weston and Loblaw to create Canadian retailer giant
Loblaw completes Shoppers Drug Mart acquisition
CVS Health expand Naloxone accessibility in five states